ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2464

Clinimetric and Drug Use Differences in Colombian Patients with Early and Established Rheumatoid Arthritis

Jorge Florez-Suarez1, Paul Mendez2, Edna Bermudez1, Paola Coral2 and Gerardo Quintana-Lopez1,3, 1Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogotá, Colombia, 2Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogota, Colombia, 3School of medicine, Universidad Nacional de Colombia, Bogotá, Colombia

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Clinical Response, DMARDs, Early Rheumatoid Arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Current guidelines for RA treatment are focused on the importance of defining the duration of symptoms before diagnosis to achieve better outcomes. This concept allows the definition of Early (ERA) and established RA (RA). Evidence suggest that ERA patients achieve better outcomes in terms of disease activity, bone erosions and survival. This study shows the clinimetric and treatment differences between patients with ERA and RA in an excellence clinical care center in Colombia.

Methods:

The study used a cohort of Colombian patients with RA (Satisfying ACR/EULAR classification criteria). Data collected from clinical records were: RA classification, disease activity using DAS-28 ESR (DAS-28), number of synthetic and biological DMARDs used, and their respective dose. Data was obtained for 0, 3, 12, 24, and 36 months of follow-up. Patients were classified as ERA or RA. Mean DAS-28, synthetic DMARDs dose, number of synthetic and biologic DMARDs used from each period of time were calculated.    

Results:

An overall of 805 patients were included; 147 patients with ERA and 658 patients with RA. 82% of patients are seropositive. Both group of patients began with mean DAS-28 corresponding to moderate activity (ERA: 3.67; RA: 3.87). Mean DAS-28 achieve remission since 3 months of follow-up for ERA group. Mean DAS-28 for RA did not achieve remission, but low activity was achieved since 3 months. Mean synthetic and biologic DMARDs use was constantly increasing in both groups, but the number was always greater in RA. About mean DMARD dose for specific drugs, weekly MTX dose stands as it was initially greater in RA, but it achieves an upper limit since 12 months of follow-up. ERA Mean weekly MTX dose constantly increase until 36 months, even surpassing RA mean dose.

Conclusion:

Results are consistent with existent evidence of disease behavior in other populations, by showing that Colombian patients with ERA achieve lower disease activity and even remission, and use less medication in comparison to RA patients. DMARD doses were greater in RA group, except for MTX.

 

Reference:

Casta–eda S, Navarro F, Fern‡ndez-Carballido C, Tornero C, Marced E, Corteguera M. Diferencias en el manejo de la artritis reumatoide precoz y establecida. Reumatolog’a Cl’nica. 2011;7(3):172-178.

 



Disclosure: J. Florez-Suarez, None; P. Mendez, Novartis, 5,AbbVie Inc., 5; E. Bermudez, None; P. Coral, None; G. Quintana-Lopez, Janssen, 5.

To cite this abstract in AMA style:

Florez-Suarez J, Mendez P, Bermudez E, Coral P, Quintana-Lopez G. Clinimetric and Drug Use Differences in Colombian Patients with Early and Established Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/clinimetric-and-drug-use-differences-in-colombian-patients-with-early-and-established-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinimetric-and-drug-use-differences-in-colombian-patients-with-early-and-established-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology